Takeda to discontinue Phase III trial of alisertib in relapsed or refractory PTCL patients
Alisertib is an oral, selective, inhibitor of Aurora A kinase being investigated by Takeda to treat small cell lung cancer. The decision to discontinue follows the results of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.